Skip to main content
. 2018 Mar 30;9(24):17117–17132. doi: 10.18632/oncotarget.24965

Figure 4.

Figure 4

(A–D) Biodistribution of 89Zr-DFO-nimotuzumab in EGFR-positive MDA-MB-468, DLD-1, and control (very low EGFR expressing) MDA-MB-435 xenografts at 4, 24, 72 and 168 h post injection. Athymic CD-1 nude mice xenografts were injected via a tail vein with 10 MBq 10 μg of 89Zr-DFO-nimotuzumab followed by biodistribution studies. Uptake in MDA-MB-468 and DLD-1 tumors was significantly higher than in control MDA-MB-435 at 24 (* p < 0.05) and 168 h (** p < 0.05) post injection.